Furthermore, a retrospective analyze has shown that there was no predictive value of PD-L1 expression in squamous cell carcinoma in contrast to adenocarcinoma (6), suggesting that PD-L1 may not be an ideal biomarker for LUSC patients who received immunochemotherapy. This evidence concerns the gene CD274 and adenocarcinoma.